Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quinisocaine (also known as dimethisoquin) is a topical local anesthetic primarily used as an antipruritic agent to relieve itching and minor skin irritations. It belongs to the class of amino amide anesthetics and acts by blocking nerve conduction when applied locally. The mechanism of action involves inhibition of voltage-dependent sodium channels in nerve tissue, resulting in reversible sensory and motor paralysis in the area of application. Additionally, it has been shown to inhibit nicotinic acetylcholine receptors (notably α4β4 and α4β2 subtypes), which may contribute to its pharmacological effects[1][3][5]. Quinisocaine is classified under ATC code D04AB05 for dermatological use as an antipruritic and topical anesthetic.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on quinisocaine.